The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study.
 
Keun Wook Lee
Honoraria - Boryung; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; ISU ABXIS; MSD; Vifor Pharma
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); GC Pharma (Inst); InventisBio (Inst); Leap Therapeutics (Inst); LSK BioPharma (Inst); MacroGenics (Inst); MedPacto (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Trishula Therapeutics (Inst); Y-Biologics (Inst); Zymeworks (Inst)
 
Li-Yuan Bai
Honoraria - CStone Pharmaceuticals; Ipsen; Lilly; Ono Pharmaceutical; Pfizer; SynCoreBio
Consulting or Advisory Role - Bristol-Myers Squibb; Zai Lab
Research Funding - Eisai
 
Minkyu Jung
Employment - Ensol Biosciences (I)
Stock and Other Ownership Interests - Ensol Biosciences; Ensol Biosciences (I)
Honoraria - Celltrion; Lilly
 
Jieer Ying
No Relationships to Disclose
 
Young Hyuck Im
No Relationships to Disclose
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Jae Yong Cho
No Relationships to Disclose
 
Sang Cheul Oh
No Relationships to Disclose
 
Yee Chao
No Relationships to Disclose
 
Huiyan Li
Employment - BeiGene Beijing
Stock and Other Ownership Interests - BeiGene Beijing
Travel, Accommodations, Expenses - BeiGene Beijing
 
Ping Zhou
Employment - BeiGene Beijing
Stock and Other Ownership Interests - BeiGene
 
Yuanyuan Bao
Employment - BeiGene Beijing
Stock and Other Ownership Interests - BeiGene
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Blueprint Medicines; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks